ORIGINAL ARTICLE

Subxifoid versus transthoracic thoracoscopic lobectomy: Results of a retrospective analysis before and after matching analysis

Claudio Andreetti¹, Valentina Peritore¹, Mohsen Ibrahim¹, Antonio Gagliardi¹, Giacomo Argento¹, Giulio Maurizi¹, Leonardo Teodonio¹, Nicola Serra², Erino Angelo Rendina¹, Mario Santini³ & Alfonso Fiorelli³

¹ Thoracic Surgery Unit, Sant’Andrea Hospital, University of Rome La Sapienza, Rome, Italy
² Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy
³ Thoracic Surgery Unit, University of Campania Luigi Vanvitelli, Naples, Italy

Keywords
Conventional thoracoscopy; lobectomy; lung cancer; subxifoid thoracoscopy.

Correspondence
Alfonso Fiorelli, Thoracic Surgery Unit, Università della Campania “Luigi Vanvitelli”, Piazza Miraglia, 2, I-80138 Naples, Italy. Tel: +390815665228 Fax: +390815665230 Email: alfonso.fiorelli@unicampania.it

Received: 7 September 2020; Accepted: 25 November 2020.

doi: 10.1111/1759-7714.13778
Thoracic Cancer 12 (2021) 1279–1290

Abstract

Background: Here, we report our initial experience with subxifoid video-assisted thoracoscopic surgery (SVATS) lobectomy for the management of primary lung cancer, and compared the outcomes of SVATS with those of conventional transthoracic VATS (CVATS) lobectomies to validate its feasibility and usefulness.

Methods: The clinical data of consecutive patients undergoing VATS lobectomy via SVATS or CVATS for lung cancer were retrospectively compared. The endpoints were to evaluate the statistical differences in surgical results, postoperative pain (measured with visual analog scale [VAS] scores at 8 hours, Day 1, Day 2, Day 3, at discharge, one month and three months after surgery) and paresthesia (measured at one-month, and three months after surgery). The two groups were compared before and after matching analysis.

Results: Our study population included 223 patients: 84 in the SVATS and 139 in the CVATS group. The two groups were not comparable for sex ($P=0.001$), preoperative comorbidity as cardiopathy ($P=0.007$), BMI value ($P=0.003$), left-sided procedure ($P=0.04$), tumor stage ($P=0.04$), and tumor size ($P=0.002$). These differences were overcome by propensity score matching (PSM) analysis that yielded two well-matched groups which included 61 patients in each group. Surgical outcomes including blood loss, hospital stay and complications were similar before and after matching analysis, but SVATS compared to CVATS was associated with significant reduction of postoperative pain and paresthesia at one ($P=0.001$), and three months ($P<0.0001$) after surgery. The two groups were compared before and after matching analysis.

Conclusions: SVATS lobectomy is a feasible and safe strategy with surgical outcomes similar to CVATS lobectomy but with less postoperative pain and paresthesia.

Key points

Significant findings of the study
- Subxifoid thoracoscopic lobectomy is a feasible and safe procedure, with potential benefits in terms of postoperative pain and paresthesia compared to conventional thoracoscopic lobectomy
- Our results showed that surgical outcomes including blood loss, hospital stay, morbidity and mortality are similar but subxifoid thoracoscopy was associated with significant reduction of postoperative pain and paresthesia.
What this study adds
- Subxifoid thoracoscopy is a safe procedure; compared to conventional trans-thoracic thoracoscopy, it avoids intercostal incisions, and spares nerve trauma, resulting in a reduction of postoperative pain and paresthesia.

Introduction
Since its introduction in the early 1990s, video-assisted thoracoscopic surgery (VATS) has become the preferred approach for the management of early stage lung cancer. Compared to standard thoracotomy, VATS is associated with a significant reduction in postoperative pain, morbidity and mortality, and hospitalization.\textsuperscript{1–4} Conventional VATS (CVATS) is performed through single or multiple transthoracic incisions that may injure the intercostal nerves, resulting in chest wound pain and paresthesia. More recently, the subxiphoid VATS (SVATS) approach has been proposed as an alternative to CVATS for a variety of thoracic procedures including lung cancer resection.\textsuperscript{4–11} The procedure is performed using only a subxiphoid incision, through which the specimen is also retrieved. Since the intercostal nerve is lacking in the subxiphoid area, this strategy may reduce acute and chronic chest wound pain.\textsuperscript{12,13} However, SVATS is a demanding procedure which is performed in very few high-volume centers. Thus, there are still concerns regarding the wide feasibility and real advantages of SVATS compared to CVATS.\textsuperscript{14}

In this study, we report our initial experience with SVATS lobectomy for the management of lung cancer. We evaluated the validity of this approach by comparison of surgical outcomes, postoperative pain and paresthesia of SVATS lobectomies with those of CVATS lobectomies. This article is presented in accordance with the STROBE reporting checklist which is provided as an additional file.

Methods

Study design
This was a retrospective comparative study of patients who underwent lobectomy for management of lung cancer via either the SVTAS or CVATS approaches between January 2015 and January 2020. The patients were not randomized, but underwent SVTAS or CVATS at the surgeons’ discretion. The end-points of the study were to evaluate: (i) the feasibility and safety of the SVTAS approach by comparison of the surgical outcomes of SVTAS with those of CVATS lobectomies; and (ii) whether SVTAS was associated with potential benefits over CVTAS with regard to postoperative pain and paresthesia.

The study design was approved by the Local Ethics Committees of University of Campania Luigi Vanvitelli (code number: 326-20); all patients gave their written informed consent for the surgery, and were aware that all their data could be used anonymously for scientific purposes only.

Participants
The clinical data of all patients undergoing lobectomy for lung cancer via SVTAS or CVTAS approach and with complete follow-up regarding surgical outcomes, postoperative pain and paresthesia were included in the study. We excluded: (i) patients undergoing open lobectomy; (ii) patients undergoing VATS resection different from lobectomy (ie, wedge resection, segmentectomy or bilobectomy) or undergoing lobectomy with concomitant decortication and/or chest wall injury or resection; (iii) patients with a history of previous thoracic surgical procedures and/or of chronic pain, or taking regular analgesics; and (iv) patients with incomplete follow-up.

The choice of approach (CVTAS or SVTAS) was made by surgeons based on tumor and patient characteristics. Since 2016, with increasing experience in VATS, lobectomy has been performed using a SVTAS approach in selected patients. Indications for SVTAS were peripheral small tumors, without lymph node involvement. Patients with pleural adhesions, BMI >30 kg/m\textsuperscript{2}, and cardiac diseases including cardiomegaly and arrhythmia were not evaluated for SVTAS.

All patients received the same preoperative workup including computed tomographic (CT) scanning, integrated with positron emission tomographic (PET-CT) scanning, and standard cardiopulmonary functional tests. Invasive mediastinal procedures were carried out only in cases of suspicion of mediastinal involvement on radiological examination. For each patient, demographic data, ie, age at operation, gender, body mass index (BMI); preoperative comorbidity; pulmonary function status; tumor characteristics (ie, side, size, stage); operative outcomes (ie, operative time, blood loss, intraoperative complications); postoperative results (ie, output drainage, length of chest drainage, length of hospital stays, morbidity and mortality); and postoperative pain and paresthesia were recorded.

Subxifoid VATS lobectomy
C. Andreetti et al.
Surgical procedure

CVATS and SVATS were performed under general anesthesia, and single-lung ventilation. Surgical equipment included endoscopic articulating linear cutters, long curved endoscopic surgical instruments, curved suction, and a 10 mm 30 grade thoracoscope. Energy-based devices and surgical endoclips were also used to divide small vessels and/or thin portions of the fissures, and for lymphadenectomy.

CVATS lobectomy was performed exclusively via a standard three-port approach. The patient was positioned in lateral decubitus and the surgeon was positioned in front of the patient. A 4 cm incision was carried out within the fourth intercostal space on the anterior axillary line, and protected by a wound retractor. This access was used for working instruments, staplers, and for retrieving specimens. A 10 mm incision for the camera was performed within the seventh intercostal space in the mid-axillary line, and a 20 mm incision for grasping the lung, dissection and for stapling was made within the sixth or seventh intercostal space in the posterior axillary line.

SVATS was performed using a single incision in the subxiphoid space. The patient was placed in a lateral decubitus position with a 30 degree lateral inclination (Fig 1a). Both the surgeon and the assistant were placed contralaterally to the surgical lung. A 4 cm long transversal incision was made below the xifoid process. The skin, subcutaneous tissue and fascia of the rectus abdominis muscle were cut to expose the xiphoid cartilage. The tunnel close to the xifoid process was bluntly dissected with a finger, and the pleural cavity was entered above the diaphragm. A wound protector was then inserted to obtain an optimal view (Fig 1b).

Both procedures (CVATS and SVATS) followed the classic principles of pulmonary resections. The first step was to explore the pleural cavity for any unexpected disease and to resect adhesions. Next, the lobectomy was performed. The target pulmonary veins (Fig 2a), arteries (Fig 2b), fissures (Fig 2c), and bronchus (Fig 2d) were divided sequentially, with appropriate endoscopic staplers. Then, the specimen was removed using an endoscopic retrieval bag, and extended lymphadenectomy performed to include stations 2R, 4R, 7, 8, and 9 for right-sided cancers and stations 4L, 5, 6, 7, 8, and 9 for left-sided cancers. The bronchial stump was checked under water for air leaks, and a drain was inserted through the camera port for CVATS or via subxiphoid incision for SVATS and positioned to the thoracic apex. It was then connected to a drainage bottle.

After surgery, the patient was usually transferred to an intensive care unit and the next day to the postoperative ward. The drain was removed when there was no air leakage, and the daily output was less than 300 mL.

Surgical outcome

Surgical outcome was assessed by collecting operative and postoperative data. Operative data included operative time (minutes), intraoperative blood loss (mL), and complications (ie, vascular injury, cardiac complications, etc). Postoperative data included output drainage, length of chest drainage, length of hospital stay and morbidity and mortality.

Postoperative pain control

The protocol for postoperative pain management was the same for each group. Pre-emptive wound analgesia with ropivacaine was performed before incisions. At the end of the operation, a multilevel intercostal nerve block using ropivacaine (7.5 mg diluted in 20 mL of saline), 4 mL for each intercostal space, was performed including the intercostal level of the incision and one level above and below. During the postoperative course, oral paracetamol (1 g), and oral Ketorolac (20 mg) was administered every 6 hours.
If the visual analog scale (VAS) score was higher than 4, intravenous injection of morphine (0.1 mg/kg) was administered.

**Postoperative pain evaluation**

Maximum pain scores were evaluated using the VAS with 11-point levels, ranging from 0 (no pain) to 10 (the worst pain experienced). Pain was evaluated postoperatively at eight hours, on days 1, 2, and 3 and at discharge. All patients were subsequently followed-up in the outpatient department by general enquiry at the time of the first and third months to evaluate any residual pain.

**Postoperative paresthesia evaluation**

Paresthesia was assessed using data from previously reported studies. The most common characteristics were “pins and needles”, a sensation of “abnormal swelling”, and “numbness”. They were graded as follows: mild, moderate, and severe. The paresthesia was recorded one and three months after surgery.

**Study size**

We calculated our sample size based on the primary outcome measure as the VAS score. Based on previous studies, a sample size of 40 patients per each group was calculated, assuming an intention to detect an effect size of 0.65 in the mean difference of the VAS score with 80% power and a type I error rate of 0.05. In anticipation of excluding patients after propensity score matching (PSM) analysis, we extended the number of patients before any comparative analysis.

**Statistical analysis**

The Kolmogorov-Smirnov test and graphic histograms were used to check the normality/skewness of continuous variables data in subgroups before further analysis, and appropriate statistical tests were chosen accordingly. Data are summarized as mean and standard deviation (SD) for continuous variables, and absolute number and percentage for categorical variables. We used a Student’s t-test for normally distributed variables to compare means, the Mann-Whitney test to compare non-normally distributed variables, and a chi-square test to compare categorical data. Repeated measures analysis of variance (ANOVA) test, corrected with Bonferroni post-hoc test, if indicated, was used for comparison of symmetric continuous variables measured at different time-points.

To minimize the influence of clinical confounders on outcomes, PSM analysis between the two groups was performed to create comparable groups of patients.
ratio was used and the propensity score was constructed by using the following covariates: age (<70 or ≥70 year-old); BMI (< 25 or ≥25); ppoFEV1% (≤40% or >40%); cardiac disease (yes or no); involved side and type of resection (right upper or right lower lobectomy, left upper lobectomy and left lower lobectomy); tumor size (≤30 mm or >30 mm); stage (stage I–II or stage III–IV); and major postoperative complications (yes or no). Specifically, we sought to match each SVATS patient to CVATS patient who had a propensity score that was identical to nine digits. If this match could not be found, the algorithm proceeded sequentially to the next highest digit match on propensity score to make “next best” matches, in a hierarchical sequence until no more matches could be made. Once a match was made, previous matches were not reconsidered before making the next match. More detailed information is reported as a supplementary file. A P-value < 0.05 was considered statistically significant. MedCalc statistical software (Version 12.3, Mariakerke, Belgium) and PASS 11 (NCSS, LLC, Kaysville, Utah, USA) were used for the analysis.

Results

In the study period, 570 patients underwent lobectomy for cancer, and 236 of these were performed via CVATS or SVATS. In the CVATS group, 10 patients were excluded. In one case lobectomy was associated with the resection of parietal pleura, while in three there was a conversion to thoracotomy due to a vascular (n = 2) or bronchial lesion (n = 1). Five patients presented with chronic postoperative pain, and one had previous chest surgery. In the SVATS group, three patients were excluded as they were converted to thoracotomy for vessel injury (n = 1), for technical difficulties and bleeding (n = 1), and for arrhythmia and hypotension (n = 1). Thus, our study population included a total of 223 patients for final analysis: 84 in the SVATS group, and 139 in the CVATS group. The data are summarized in Table 3. There were no significant differences between the SVATS group and the CVATS group in blood loss, drainage time and output, length of hospital stay before and after matching analysis. Operative time was longer in the SVATS compared with the CVATS group in unmatched (159 ± 13 vs. 126 ± 6.3, P < 0.0001), and matched populations (161 ± 23 vs. 119 ± 8.3, P < 0.0001). The incidence of overall postoperative complications was 4% and 6% in unmatched and matched populations, respectively. The SVATS group compared to the CVATS group showed no statistical differences before (P = 0.99) and after matching analysis (P = 0.69). There were no perioperative deaths, with 30- and 90-day survival of 100% in both groups.

Postoperative pain

The data are summarized in Table 4. There was no significant difference between SVATS and CVATS in the first eight hours postoperatively (1.7 ± 0.8 vs. 1.9 ± 0.9, P = 0.54), while significant differences were found at day 1 (3.9 ± 0.7 vs. 4.9 ± 0.7; P = 0.001), day 2 (3.4 ± 0.8 vs. 4.0 ± 0.8; P = 0.004), day 3 (2.7 ± 0.7 vs. 3.3 ± 0.8; P = 0.009), at discharge (2.2 ± 0.5 vs. 2.8 ± 0.5; P = 0.001), one month (1.2 ± 0.5 vs. 1.6 ± 0.4; P = 0.007) and three months (0.6 ± 0.5 vs. 1.0 ± 0.7; P = 0.01) after surgery (Fig 4a). ANOVA test showed that SVATS was associated with significant reduction of VAS during the entire postoperative follow-up (P < 0.001). Similar results were observed in the matched analysis (P = 0.04). Additionally, the CVATS group compared to the SVATS group had a higher rate of patients (4% vs. 15%, P = 0.04) who needed morphine to manage their pain at a comfortable level (VAS ≤4).

Postoperative paresthesia

Before matching analysis, the incidence of paresthesia in the SVATS group compared to the CVATS groups was 20% vs. 42% (P = 0.001) one month after surgery, and 6% vs. 34% (P < 0.0001) three months after surgery. After matching analysis, paresthesia was also significantly lower in the SVATS than in the CVATS groups one month (19% vs. 41%; P = 0.001) and three months (5% vs. 33%; P < 0.0001) after surgery. In all cases, the paresthesia level did not limit the patients’ daily activities.
Table 1 Patient characteristics before and after matching analysis

| Variable                        | All   | SVATS | CVATS | P-value |
|---------------------------------|-------|-------|-------|---------|
| **Before matching analysis**    |       |       |       |         |
| Number of patients              | 223   | 84    | 139   | —       |
| Age (year-old)                  | 63.3 ± 7.6 | 63.3 ± 1.8 | 62.9 ± 7.2 | 0.82    |
| Sex (male)                      | 142   | 43 (51%) | 99 (71%) | 0.001   |
| BMI                             | 26 ± 5.9 | 22 ± 3.8 | 28 ± 4.9 | 0.003   |
| Preoperative comorbidity        | 71    | 26 (31%) | 45 (32%) | 0.74    |
| COPD                            | 24    | 3 (3%)   | 21 (15%) | 0.007   |
| Cardiopathy                     | 11    | 3 (6%)   | 9 (6%)  | 0.87    |
| Diabetes                        | 16    | 6 (7%)   | 15 (11%) | 0.36    |
| Hypertension                    |       |         |       |         |
| Functional data                 | 2.3 ± 0.9 | 2.3 ± 0.4 | 2.2 ± 0.6 | 0.73    |
| FEV1                            | 383 ± 59 | 389 ± 60 | 376 ± 56 | 0.15    |
| 6MWT                            |       |         |       |         |
| **After matching analysis**     |       |         |       |         |
| Number of patients              | 122   | 61     | 61    | —       |
| Age (year-old)                  | 63.3 ± 4.6 | 63.1 ± 3.8 | 63.2 ± 8.2 | 0.92    |
| Sex (male)                      | 61 (50%) | 30 (49%) | 31 (51%) | 0.85    |
| BMI                             | 22 ± 6.8 | 22 ± 3.8 | 22 ± 8.9 | 0.84    |
| Preoperative comorbidity        | 37 (30%) | 18 (29%) | 19 (31%) | 0.79    |
| COPD                            | 5 (4%)  | 2 (3%)   | 3 (5%)  | 0.63    |
| Cardiopathy                     | 11 (9%) | 4 (6%)   | 7 (11%) | 0.33    |
| Diabetes                        | 10 (8%) | 4 (6%)   | 6 (10%) | 0.49    |
| Hypertension                    |       |         |       |         |
| Functional data                 | 2.3 ± 0.6 | 2.3 ± 0.5 | 2.2 ± 0.8 | 0.85    |
| FEV1                            | 384 ± 67 | 385 ± 41 | 383 ± 75 | 0.64    |
| 6MWT                            |       |         |       |         |
Postoperative pain and chest wall paresthesia remain unsolved issues for thoracic surgeons. They also still occur when surgical resection is performed using CVATS. The reduction in the number of ports does not affect postoperative pain, confirming that port location could be more important than numbers.19–21 Therefore, in the last few years there has been a growing interest in performing VATS using the subxiphoid route in order to avoid intercostal incisions, and spare nerve trauma. Initially, SVATS was used for the management of pneumothorax,22,23 and mediastinal tumors.24,25 Then, a few high-volume centers also performed anatomical lung resections using SVATS with satisfactory short-term results.4–11 However, it is still debatable whether SVATS lobectomy presents real advantages over CVATS lobectomy. Four reports,5–8 summarized in Table 5, previously evaluated this issue with contrasting results as SVATS was associated with shorter hospitalization in two studies,6,8 and patients with lower postoperative pain were reported in three.5,7,8 The small cohorts of patients, subjectivity of pain reporting, and lack of standardized pain control protocols used were the main limitations of these studies. A Randomized Controlled Trial (RCT), registered in ClinicalTrials.gov.

### Table 2 Pathological data of study population

| Variable                          | All      | SVATS    | CVATS    | P-value |
|-----------------------------------|----------|----------|----------|---------|
| **Before matching analysis**      |          |          |          |         |
| Number of patients                | 223      | 84 (38%) | 139 (62%)| —       |
| Type of lobectomy                 | 85 (38%) | 50 (59%) | 35 (25%) | <0.0001 |
| RUL                               | 21 (9%)  | 10 (12%) | 11 (8%)  | 0.30    |
| ML                                | 50 (22%) | 8 (9%)   | 42 (30%) | 0.0003  |
| RLL                               | 38 (17%) | 10 (12%) | 28 (20%) | 0.11    |
| LUL                               | 29 (14%) | 6 (8%)   | 23 (17%) | 0.04    |
| Histology                         | 71 (32%) | 27 (32%) | 44 (32%) | 0.93    |
| Squamous carcinoma                | 128 (57%)| 50 (59%) | 78 (56%) | 0.61    |
| Adenocarcinoma                    | 24 (11%) | 7 (9%)   | 17 (12%) | 0.36    |
| Large cell carcinoma              |          |          |          |         |
| Tumor size (mm)                   | 35 ± 13  | 23 ± 0.8 | 37 ± 11  | 0.002   |
| Pathological status               | 180 (81%)| 73 (86%) | 108 (77%)| 0.11    |
| Stage I                           | 27 (12%) | 9 (11%)  | 18 (13%) | 0.62    |
| Stage II                          | 15 (7%)  | 2 (3%)   | 13 (9%)  | 0.04    |
| **Stage III**                     |          |          |          |         |
| Nodal station                     | 6.3 ± 0.7| 6.3 ± 0.7| 6.4 ± 0.9| 0.85    |
| Nodal number                      | 9.3 ± 0.8| 9.2 ± 0.7| 9.3 ± 1.3| 0.75    |
| Nodal upstaging                   | 28       | 7 (8%)   | 18 (13%) | 0.29    |
| **After matching analysis**       |          |          |          |         |
| Number of patients                | 122      | 61       | 61       |         |
| Type of lobectomy                 | 67 (55%) | 36 (57%) | 31 (51%) | 0.46    |
| RUL                               | 12 (10%) | 7 (12%)  | 5 (8%)   | 0.54    |
| ML                                | 13 (10%) | 6 (9%)   | 7 (11%)  | 0.77    |
| RLL                               | 16 (13%) | 7 (12%)  | 9 (15%)  | 0.59    |
| LUL                               | 14 (12%) | 5 (8%)   | 9 (15%)  | 0.25    |
| Histology                         | 40 (33%) | 19 (31%) | 21 (34%) | 0.70    |
| Squamous carcinoma                | 67 (55%) | 35 (57%) | 32 (52%) | 0.58    |
| Adenocarcinoma                    | 15 (12%) | 7 (12%)  | 8 (14%)  | 0.78    |
| Large cell carcinoma              |          |          |          |         |
| Tumor size (mm)                   | 27 ± 0.7 | 26 ± 0.5 | 28 ± 0.9 | 0.25    |
| Pathological status               | 102 (84%)| 52 (85%) | 50 (82%) | 0.62    |
| Stage I                           | 15 (12%) | 7 (12%)  | 8 (13%)  | 0.78    |
| Stage II                          | 5 (4%)   | 2 (3%)   | 3 (5%)   | 0.64    |
| Stage III                         |          |          |          |         |
| Nodal station                     | 6.4 ± 0.9| 6.4 ± 0.3| 6.4 ± 0.3| 0.87    |
| Nodal number                      | 9.5 ± 1.4| 9.5 ± 1.7| 9.5 ± 2.3| 0.79    |
| Nodal upstaging                   | 9 (7%)   | 4 (6%)   | 5 (8%)   | 0.73    |
reduction of VAS during the entire postoperative follow-up (*ANOVA test showed that SVATS was associated with significant reduction of VAS during the entire postoperative course. Although a trend of SVATS lobectomy was considered as an ideal candidate for SVATS. In fact, they had peripheral and small cancer, without lymph node involvement and pleural adhesions, and low BMIs. Most of the procedures were right-sided, with no complex resections such as sleeve lobectomy with bronchial or artery resection and reconstruction, and chest wall resection was performed as in other studies.

When we compared the surgical outcomes such as LHOS, postoperative morbidity and mortality between SVATS and CVATS, no significant differences were found, supporting the safety of the SVATS procedure. Our results were in line with those of Song et al. and Yang et al., while Pfeuty and Lenot and Chen et al. found that SVATS was associated with lower LHOS compared to CVATS. The increased use of digital drainage devices and the ERAS program for SVATS in the series by Pfeuty and Lenot, and the higher rate of wound infection for CVATS group in the series by Chen et al. could explain the different results.

Second, SVATS compared to CVATS was associated with a significant reduction in acute postoperative pain during the entire postoperative course. Although a trend

Table 3 Operative and postoperative data

| Variables                                    | All patients | SVATS | CVATS | P-value |
|----------------------------------------------|--------------|-------|-------|---------|
| Before matching analysis                     |              |       |       |         |
| Number of patients                           | 223          | 84    | 139   | —       |
| Operation time (hours)                       | 137 ± 29     | 159 ± 13 | 126 ± 6.3 | <0.0001 |
| Intraoperative blood loss (mL)               | 208 ± 16     | 210 ± 13 | 205 ± 23 | 0.36    |
| Daily chest drainage volume (mL)             | 193 ± 49     | 180 ± 43 | 200 ± 59 | 0.31    |
| Chest tube removal (days)                    | 3.4 ± 0.5    | 3.1 ± 0.7 | 3.6 ± 0.9 | 0.31    |
| Length of hospital stay (days)               | 4.7 ± 1.3    | 4.5 ± 1.1 | 4.8 ± 1.0 | 0.46    |
| Complications (total)                        | 8 (4%)       | 3 (3%) | 5 (3%) | 0.99    |
| Prolonged air leak (>5 days)                 | 3 (1%)       | 1 (1%) | 2 (1%) |         |
| Atelectasis                                  | 2 (0.7%)     | 0 ()   | 2 (1%) |         |
| Atrial fibrillation                          | 3 (1%)       | 2 (2%) | 1 (0.7%) |         |
| After matching analysis                      | 122          | 61    | 61    | —       |
| Number of patients                           |              |       |       |         |
| Operation time (hours)                       | 137 ± 29     | 161 ± 23 | 119 ± 8.3 | <0.0001 |
| Intraoperative blood loss (mL)               | 210 ± 34     | 208 ± 53 | 210 ± 29 | 0.21    |
| Daily chest drainage volume (mL)             | 190 ± 39     | 189 ± 34 | 190 ± 65 | 0.28    |
| Chest tube removal (days)                    | 3.5 ± 0.6    | 3.4 ± 0.8 | 3.5 ± 0.7 | 0.41    |
| Length of hospital stay (days)               | 5.2 ± 1.3    | 5.1 ± 1.4 | 5.2 ± 1.2 | 0.31    |
| Complications (total)                        | 7 (6%)       | 3 (5%) | 4 (6%) | 0.69    |
| Prolonged air leak (>5 days)                 | 3 (2%)       | 1 (2%) | 2 (3%) |         |
| Atelectasis                                  | 1 (1%)       | 0 ()   | 1 (2%) |         |
| Atrial fibrillation                          | 3 (2%)       | 2 (3%) | 1 (2%) |         |

Table 4 Postoperative VAS score

| VAS scores                  | SVATS | CVATS | P-value* |
|-----------------------------|-------|-------|----------|
| Before matching analysis    |       |       |          |
| 8 hours after operation     | 1.7 ± 0.8 | 1.9 ± 0.9 | 0.54     |
| Day 1 after operation       | 3.9 ± 0.7 | 4.9 ± 0.7 | 0.001    |
| Day 2 after operation       | 3.4 ± 0.8 | 4.0 ± 0.8 | 0.004    |
| Day 3 after operation       | 2.7 ± 0.7 | 3.3 ± 0.8 | 0.009    |
| At discharge                | 2.2 ± 0.5 | 2.8 ± 0.5 | 0.001    |
| 1 month after operation     | 1.2 ± 0.5 | 1.6 ± 0.4 | 0.007    |
| 3 months after operation    | 0.6 ± 0.5 | 1.0 ± 0.7 | 0.01     |
| After matching analysis     |       |       |          |
| 8 hours after operation     | 1.6 ± 0.6 | 1.9 ± 0.4 | 0.17     |
| Day 1 after operation       | 4.0 ± 0.7 | 5.0 ± 0.7 | 0.002    |
| Day 2 after operation       | 3.4 ± 0.8 | 4.1 ± 0.8 | 0.01     |
| Day 3 after operation       | 2.9 ± 0.7 | 3.4 ± 0.7 | 0.02     |
| At discharge                | 2.4 ± 0.5 | 2.8 ± 0.5 | 0.01     |
| 1 month after operation     | 1.3 ± 0.4 | 1.7 ± 0.3 | 0.01     |
| 3 months after operation    | 0.5 ± 0.3 | 1.0 ± 0.6 | 0.01     |

*ANOVA test showed that SVATS was associated with significant reduction of VAS during the entire postoperative follow-up (P < 0.001) before and after matching analysis.
was seen during the first eight postoperative hours, the difference became more evident in the following days, and at discharge. In theory, the residual effects of general anesthesia still influenced the pain perception in the immediate postoperative period. Our results were in line with all previous authors but Pfeuty and Lenot who found no significant difference between SVATS and CVATS in terms of postoperative pain, probably due to the different protocol of locoregional pain management used for the two groups. CVATS patients had a paravertebral catheter with continuous analgesia, during a median of two days, whereas the SVATS patients received a local one-shot subxiphoid and intercostal block. However, the same authors found that SVATS was associated with a significant reduction of home morphine use at day seven to manage their pain at a comfortable level (NRS < 3). Similarly, also in our series, CVATS had a higher rate of patients who needed morphine to manage their pain at a comfortable level (VAS ≤4), supporting the evidence of the superiority of SVATS over CVATS for postoperative pain control. Suda et al. also found that the consumption of morphine was significantly reduced after thymectomy performed with SVATS than with CVATS. The damage to the intercostal nerve is the main cause of postoperative pain after thoracic procedures. Using the subxiphoid route does not injure the intercostal nerve during the procedure because there is no bone structure or intercostal nerve in the subxiphoid incision. Yet, a chest drain is not inserted through the intercostal space so it cannot damage the intercostal nerve during patient mobilization. Thus, all these reasons may probably explain the decrease in postoperative pain associated with SVATS. Furthermore, patients had less postoperative pain and lower rates of paresthesia one and three months after SVATS. In theory, SVATS might solve the postoperative chronic persistent pain caused by the intercostal incision experienced by some patients, but more studies are still required to confirm this hypothesis.

Third, from a technical point of view, SVATS remains a more challenging procedure compared to CVATS as shown by the longer operative time observed in our study and other series. Challenges related to SVATS include the long distance between the subcutaneous incision and the hilus of the lung, small operative angle, and interference.

Figure 4 Subxifoid thoracoscopy compared to conventional thoracoscopy was associated with significant reduction of postoperative pain during the entire postoperative follow-up (P < 0.001) (a) before CVATS; SVATS and (b) after matching analysis CVATS; SVATS.

Table 5 Review of papers comparing SVATS versus CVATS lobectomies for lung cancer management

| Authors            | Operative time | LN resection | LHOS | Conversion | Morbidity | Mortality | Postoperative pain | Quality of life |
|--------------------|----------------|--------------|------|------------|-----------|-----------|--------------------|-----------------|
| Song et al. 2016   | Longer for SVATS | None         | None | N/A        | None      | None      | Lower for SVATS    | N/A             |
| Pfeuty & Lenot 2019| None           | None         | Lower for SVATS | None       | None      | None      | None               | None            |
| Yang et al. 2019   | Longer for SVATS | None         | None | None       | None      | None      | Lower for SVATS    | N/A             |
| Chen et al. 2020   | None           | None         | Lower for SVATS | None       | None      | None      | Lower for SVATS    | Better for SVATS |
| Present series     | Longer for SVATS | None         | None | None       | None      | None      | Lower for SVATS    | N/A             |

Thoracic Cancer 12 (2021) 1279–1290 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
| Authors                | Resections          | Operative time (minutes) | LHOS  | Conversion | Morbidity                                                                 |
|-----------------------|---------------------|--------------------------|-------|------------|---------------------------------------------------------------------------|
| Hernandez-Arenas et al. 2016 | Lob: 105, Segm: 48  | 166.9 ± 12.6             | 4.3 ± 0.4 | 13 (8.4%) | Arrhythmia: 20 (13%)                                                     |
| Liu et al. 2016       | Lob: 21, Segm: 5, Wedge: 9, Mediastinal surgery: 5 | 180 | N/A | 5 (12.5%) | Total: 4 (10%), Arrhythmia: 2 (5%), Chylothorax: 1 (2.5%), Bleeding: 1 (2.5%) |
| Song et al. 2016      | Lob: 105            | 164.97 ± 39.10           | 5.39 ± 1.31 | 2 (2%) | Total: 11 (10.5%), PAL: 2 (2%), Chylothorax: 1 (1%), Arrhythmia: 3 (3%), Total: 4 (10%), Arrhythmia: 2 (5%), Chylothorax: 1 (2.5%), Bleeding: 1 (2.5%) |
| Ali et al. 2018       | Segm: 242 (29 bilateral) | 2.14 ± 0.78              | 4.67 ± 9.54 | 15 (2.5%) | Total: 21 (8.26%), Bleeding: 1 (0.4%), Change to lob: 3 (1.2%), PAL: 6 (2.4%) |
| Pfeuty & Lenot 2019   | Lob: 51, Segm: 20, Pneum: 4 | 157 ± 37                | 2 (1–4) | 7 (9%) | Total: 18 (9%), Minor: 13 (17%), Major: 5 (7%) |
| Yang et al. 2019      | Lob: 34, Lob + wedge: 3 | 262.15 ± 40.68         | 9.23 ± 2.94 | 1 (2.7%) | Total: 3 (8.11%), Pneumonia: 1 (2.70%), Arrhythmia: 1 (2.70%), PAL: 1 (2.70%) |
| Chen et al. 2020      | Lob: 459            | 129.7 ± 2.2              | 4.24 ± 0.08 | 9 (1.96%) | Total: 29 (6.3%), Wound infection: 2 (0.44%), Subcutaneous emphysema: 2 (0.44%), Respiratory failure: 2 (0.44%), PAL: 6 (1.31%), Pulmonary embolism: 1 (0.22%), Arrhythmia: 16 (3.49) |
| Present series        | Lob: 84             | 159 ± 13                 | 4.5 ± 1.1 | None | Total: 3 (3%), PAL: 1 (1%), Arrhythmia: 2 (2%) |

Lob, lobectomy; PAL, persistent air-leaks; Pneum, Pneumonectomy; Segm, segmentectomy; wedge, wedge resection.
of surgical instruments. Thus, a BMI >30 kg/m² remains the main contraindication for SVATS as the presence of subcutaneous and mediastinal fat may impede tunnel creation between the subxiphoid wound and pleural space. Yet, during the left procedure, the intraoperative heart compression caused by the passage of instruments through the subxiphoid incision into the left chest wall may induce cardiac pulsation and arrhythmia. To overcome these limits, Pfeuty and Lenot proposed a new multiportal SVATS using three ports on the left side due to partial cardiac obstruction and relatively difficult access to the subcarinal area, and two ports for right-sided resections. Based on the authors experience, this strategy facilitated the maneuverability of the endostaplers, magnified the endoscopic view, and limited the conflict between camera and other instruments. Thus, the different SVATS approach could explain the lack of differences regarding the operative time between SVATS and CVATS, or the possibility of performing more complex procedures such as sleeve lobectomies.

The present study had several limitations; thus, our results should be evaluated with caution before drawing any definitive conclusions. The small sample size, and selection bias due to the retrospective nature of the study were the main limitations, despite PSM being performed to reduce the intergroup differences. Yet, we compared a single technique incision using SVATS versus a multiport technique incision using CVATS. In theory, the number of incisions rather than their location could affect the results. However, several reports have previously compared postoperative pain between single- versus multiport VATS and found no significant difference between the two procedures. Finally, SVATS was performed by the same surgeon (CA) while CVATS was performed by different surgeons (CA, MI, GM, and AF); thus, different skills and experiences could affect the results.

In conclusion, this study confirmed that SVATS lobectomy is a feasible and safe procedure with surgical outcomes similar to those of CVATS lobectomy, but with significant advantages in controlling postoperative pain and paresthesia. However, SVATS remains a complex procedure that needs particular skills, and appropriate endoscopic instruments. Thus, it should be performed in a high volume center and by surgeons with considerable experience using the VATS procedure. Furthermore, patient selection is crucial for the success of the procedure. Obviously, our results should be corroborated by further and larger studies to establish the potential and promising outcomes of this strategy.

Disclosure

All authors disclose no conflict of interest and no funding for this study.

References

1. Paul S, Altorki NK, Sheng S et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg 2010; 139: 366–78.
2. Boffa DJ, Dhamija A, Kosinski AS et al. Fewer complications result from a video-assisted approach to anatomic resection of clinical stage I lung cancer. J Thorac Cardiovasc Surg 2014; 148: 637–43.
3. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: A randomised controlled trial. Lancet Oncol 2016; 17 (6): 836–44.
4. Caronia FP, Fiorelli A, Ruffini E, Nicolosi M, Santini M, Lo Monte AI. A comparative analysis of Pancoast tumour resection performed via video-assisted thoracic surgery versus standard open approaches. Interact Cardiovasc Thorac Surg 2014; 19 (3): 426–35.
5. Song N, Zhao DP, Jiang L et al. Subxiphoid uniportal video-assisted thoracoscopic surgery (VATS) for lobectomy: A report of 105 cases. J Thorac Dis 2016; 8 (Suppl 3): S251–7.
6. Pfeuty K, Lenot B. Multiportal subxiphoid thoracoscopic major pulmonary resections. J Thorac Dis 2019; 11 (7): 2778–87.
7. Yang X, Wang L, Zhang C, Zhao D, Lu Y, Wang Z. The feasibility and advantages of subxiphoid uniportal video-assisted thoracoscopic surgery in pulmonary lobectomy. World J Surg 2019; 43 (7): 1841–9.
8. Chen J, Volpi S, Ali JM et al. Comparison of post-operative pain and quality of life between uniportal subxiphoid and intercostal video-assisted thoracoscopic lobectomy. J Thorac Dis 2020; 12 (7): 3582–90.
9. Hernandez-Arenas LA, Lin L, Yang Y et al. Initial experience in uniportal subxiphoid video-assisted thoracoscopic surgery for major lung resections. Eur J Cardiothorac Surg 2016; 50 (6): 1060–6.
10. Liu CC, Shih CS, Liu YH, Cheng CT, Melis E, Liu ZY. Subxiphoid single-port video-assisted thoracoscopic surgery. J Vis Surg 2016; 2: 112.
11. Ali J, Haiyang F, Aresu G et al. Uniportal subxiphoid video-assisted thoracoscopic anatomical segmentectomy: Technique and results. Ann Thorac Surg 2018; 106 (5): 1519–24.
12. Aresu G, Wu L, Lin L, Jiang G, Jiang L. The Shanghai pulmonary hospital subxiphoid approach for lobectomies. J Vis Surg 2016; 2: 135.
13. ElSaegh MMM, Ismail NA, Mydin MI, Nardini M, Dunning J. Subxiphoid uniportal lobectomy. J Vis Surg 2017; 3: 24.
14. Sihow AD, Dunning J. Reasons not to perform subxiphoid video-assisted thoracic surgery. J Vis Surg 2018; 4: 214.
15. Fiorelli A, Vicidomini G, Laperuta P et al. Pre-emptive local analgesia in video-assisted thoracic surgery sympathectomy. Eur J Cardiothorac Surg 2010; 37 (3): 588–93.
16 Sihoe AD, Cheung CS, Lai HK, Lee TW, Thung KH, Yim AP. Incidence of chest wall paresthesia after needlescopic video-assisted thoracic surgery for palmar hyperhidrosis. *Eur J Cardiothorac Surg* 2005; 27 (2): 313–9.

17 Fiorelli A, Pace C, Cascone R et al. Preventive skin analgesia with lidocaine patch for management of post-thoracotomy pain: Results of a randomized, double blind, placebo controlled study. *Thorac Cancer* 2019; 10 (4): 631–41.

18 Fiorelli A, Izzo AC, Frongillo EM et al. Efficacy of wound analgesia for controlling post-thoracotomy pain: A randomized double-blind study. *Eur J Cardiothorac Surg* 2016; 49 (1): 339–47.

19 Perna V, Carvajal AF, Torrecilla JA, Gigirey O. Uniportal video-assisted thoracoscopic lobectomy versus other video-assisted thoracoscopic lobectomy techniques: A randomized study. *Eur J Cardiothorac Surg* 2016; 49 (1): 339–47.

20 McElnay PJ, Molyneux M, Krishnadas R, Batchelor TJ, West D, Casali G. Pain and recovery are comparable after either uniportal or multiport video-assisted thoracoscopic lobectomy: An observation study. *Eur J Cardiothorac Surg* 2015; 47 (5): 912–5.

21 Decaluwé H. One, two, three or four ports... does it matter? Priorities in lung cancer surgery. *J Thorac Dis* 2016; 8 (12): E1704–8.

22 Wang BY, Chang YC, Chang YC et al. Thoracoscopic surgery via a single-incision subxiphoid approach is associated with less postoperative pain than single-incision transthoracic or three-incision transthoracic approaches for spontaneous pneumothorax. *J Thorac Dis* 2016; 8: S272–8.

23 Li L, Tian H, Yue W, Li S, Gao C, Si L. Subxiphoid vs intercostal single-incision video-assisted thoracoscopic surgery for spontaneous pneumothorax: A randomised controlled trial. *Int J Surg* 2016; 30: 99–103.

24 Suda T, Hachimar A, Tochii D et al. Video-assisted thoracoscopic thymectomy versus subxiphoid single-port thymectomy: Initial results. *Eur J Cardiothorac Surg* 2016; 49 (Suppl 1): i54–8.

25 Lu Q, Zhao J, Wang J et al. Subxiphoid and subcostal arch “three ports” thoracoscopic extended thymectomy for myasthenia gravis. *J Thorac Dis* 2018; 10: 1711–20.

26 https://clinicaltrials.gov/ct2/results?term=NCT03331588&Search

27 Chiu CH, Chao YK, Liu YH. Subxiphoid approach for video-assisted thoracoscopic surgery: An update. *J Thorac Dis* 2018; 10: S1662–5.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

**Appendix S1**: Supporting Information